Related Experiment Video
Updated: Sep 5, 2025
03:42
High-Speed Human Temporal Bone Sectioning for the Assessment of COVID-19-Associated Middle Ear Pathology
Published on: May 18, 2022
2.4K
[Postcovid sino-orbital mucormycosis: a case report]
V N Kolesnokov1, A A Khanamirov2, N V Boiko1
1Rostov State Medical University, Rostov-on-Don, Russia.
Vestnik Otorinolaringologii
|July 12, 2022
Summary
This case study details post-COVID sino-orbital mucormycosis in a diabetic patient. Early diagnosis and aggressive surgical and antifungal treatment are crucial for managing this severe fungal infection.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Otorhinolaryngology
Background:
- Mucormycosis is a rare but aggressive fungal infection.
- Post-COVID-19 infections, particularly mucormycosis, have emerged as a significant concern.
- Diabetes mellitus is a known risk factor for mucormycosis.
Observation:
- A 74-year-old male with diabetes mellitus developed sino-orbital mucormycosis three weeks post-COVID-19 discharge.
- Symptoms included right eye ptosis, proptosis, ophthalmoplegia, blindness, facial numbness, and periorbital edema.
- Diagnosis was confirmed via microscopy of nasal discharge; CT revealed pansinusitis with extensive destructive changes.
Findings:
- The patient underwent emergency endoscopic debridement, orbital decompression, and orbitotomy.
- Intravenous amphotericin B was initiated.
- Despite initial treatment, condition deteriorated, necessitating more aggressive surgical debridement of sinuses and orbit.
Implications:
- This case highlights the critical need for heightened awareness of mucormycosis in post-COVID-19 patients, especially those with comorbidities like diabetes.
- Prompt and aggressive multidisciplinary management, including surgical intervention and systemic antifungal therapy, is essential for improving outcomes.
- Further research into the pathogenesis and optimal treatment strategies for post-COVID-19 mucormycosis is warranted.
